Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study

Shukui Qin, Stephen L. Chan, Shanzhi Gu, Yuxian Bai, Zhenggang Ren, Xiaoyan Lin, Zhendong Chen, Weidong Jia, Yongdong Jin, Yabing Guo, Xiaohua Hu, Zhiqiang Meng, Jun Liang, Ying Cheng, Jianping Xiong, Hong Ren, Fang Yang, Wei Li, Yajin Chen, Yong Zeng, А. В. Султанбаев, Monika Pazgan−Simon, Margaryta Pisetska, Davide Melisi, Davide Melisi, Yurii Osypchuk, Ivan Sinielnikov, Tsai‐Sheng Yang, Liang Xiao, Chunxia Chen, Linna Wang, Linna Wang, Ahmed O. Kaseb, Arndt Vogel, Shukui Qin, Shukui Qin, Shukui Qin, Ahmed O. Kaseb, Arndt Vogel, Shanzhi Gu, Arndt Vogel, Zhenggang Ren, Xiaoyan Lin, Zhenggang Ren, Weidong Jia, Yongdong Jin, Yabing Guo, Xiaohua Hu, Zhiqiang Meng, Jun Liang, Ying Cheng, Jianping Xiong, Hong Ren, Jianping Xiong, Wei Li, Yajin Chen, Yong Zeng, А. В. Султанбаев, Monika Pazgan−Simon, Margaryta Pisetska, Davide Melisi, Margaryta Pisetska, Yurii Osypchuk, Ivan Sinielnikov, Tsai‐Sheng Yang, Liang Xiao, Chunxia Chen, Linna Wang, Mingxiang Zhang, Li Xu, Xianglin Yuan, Da Li, Jierer Ying, Jingdong Zhang, Tao Zhang, Kangsheng Gu, Yifu He, Kangsheng Gu, Da Jiang, Shu Zhang, Baocai Xing, Baihong Zhang, Dong Wang, Xiaofeng Zhai, Houjie Liang, Bożena Cybulska-Stopa, Mikhail Dvorkin, Daniil Stroyakovskiy, M. Nechaeva, Chia‐Jui Yen, Wei‐Wen Su, Yen‐Hao Chen, Igor Bondarenko, Lin Yang, Weijia Fang, Carlos Gómez-Martín, Min‐Hee Ryu, Hansang Kim, Jeehyun Kim, Oleg Zarubenkov